ES2171428T3 - Derivados de galantamina, un procedimiento para su preparacion y su uso como medicamentos. - Google Patents

Derivados de galantamina, un procedimiento para su preparacion y su uso como medicamentos.

Info

Publication number
ES2171428T3
ES2171428T3 ES94115959T ES94115959T ES2171428T3 ES 2171428 T3 ES2171428 T3 ES 2171428T3 ES 94115959 T ES94115959 T ES 94115959T ES 94115959 T ES94115959 T ES 94115959T ES 2171428 T3 ES2171428 T3 ES 2171428T3
Authority
ES
Spain
Prior art keywords
compounds
galantamine
medications
derivatives
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94115959T
Other languages
English (en)
Inventor
Raymond W Kosley Jr
Larry Davis
Veronica Taberna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2171428T3 publication Critical patent/ES2171428T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

ESTA SOLICITUD SE REFIERE A COMPUESTOS DE LA FORMULA EN LA QUE R1, R2, R3 Y R4 SON COMO SE DEFINEN AQUI DENTRO, CUYOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO DE DISFUNCIONES DE LA MEMORIA CARACTERIZADAS POR UNA FUNCION COLINERGICA REDUCIDA, A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN LOS COMPUESTOS Y A LOS METODOS PARA LA PRODUCCION Y USO DE LOS COMPUESTOS.
ES94115959T 1993-10-15 1994-10-10 Derivados de galantamina, un procedimiento para su preparacion y su uso como medicamentos. Expired - Lifetime ES2171428T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/137,440 US6323195B1 (en) 1993-10-15 1993-10-15 Galanthamine derivatives as acetylcholinesterase inhibitors

Publications (1)

Publication Number Publication Date
ES2171428T3 true ES2171428T3 (es) 2002-09-16

Family

ID=22477446

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94115959T Expired - Lifetime ES2171428T3 (es) 1993-10-15 1994-10-10 Derivados de galantamina, un procedimiento para su preparacion y su uso como medicamentos.

Country Status (23)

Country Link
US (2) US6323195B1 (es)
EP (2) EP0653427B1 (es)
JP (1) JP2664344B2 (es)
KR (1) KR0169114B1 (es)
CN (1) CN1039911C (es)
AT (1) ATE212348T1 (es)
AU (1) AU696249B2 (es)
CA (1) CA2118174C (es)
CZ (1) CZ287071B6 (es)
DE (1) DE69429708T2 (es)
DK (1) DK0653427T3 (es)
EG (1) EG20472A (es)
ES (1) ES2171428T3 (es)
FI (1) FI108723B (es)
IL (1) IL111274A (es)
NO (1) NO310415B1 (es)
NZ (1) NZ264683A (es)
PL (1) PL177730B1 (es)
PT (1) PT653427E (es)
RO (1) RO114133B1 (es)
RU (1) RU2114850C1 (es)
TW (1) TW363969B (es)
ZA (1) ZA948062B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
WO2000030446A1 (en) * 1998-11-23 2000-06-02 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
EE04996B1 (et) 1998-12-24 2008-04-15 Janssen Pharmaceutica N.V. Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend
US8603546B2 (en) * 1999-01-11 2013-12-10 Herbaceuticals Inc. Herbal supplement for increased muscle strength and endurance for athletes
EP1150695B1 (en) * 1999-01-11 2007-02-28 Atanas Russinov Djananov Herbal supplement for increased muscle strength and endurance for athletes
DK1086706T3 (da) * 1999-03-31 2004-03-08 Eisai Co Ltd Stabiliserede sammensætninger indeholdende nootropiske lægemidler
TW592725B (en) * 1999-10-26 2004-06-21 Janssen Pharmaceutica Nv Galantamine oral solution
EP2311463A1 (en) * 1999-12-10 2011-04-20 Bonnie M. Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
ATE263171T1 (de) 2000-03-31 2004-04-15 Sanochemia Pharmazeutika Ag Neue derivate und analoga von galanthamin
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
CA2551946A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galantamine
WO2005065662A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
EP1779867A4 (en) * 2004-07-01 2009-12-02 Eisai R&D Man Co Ltd MEANS FOR PROMOTING NERVE REVENERATION
WO2006124585A2 (en) * 2005-05-13 2006-11-23 Alza Corporation Multilayer drug system for the delivery of galantamine
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
JP2009508903A (ja) * 2005-09-22 2009-03-05 ガラントス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 認知障害を伴う疾患の治療に用いるための脳血液関門透過性が改善されたコリン作用増強剤
EP1777222A1 (en) 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
EP1937226A2 (en) * 2005-09-23 2008-07-02 Alza Corporation Transdermal galantamine delivery system
CA2721007C (en) 2008-04-14 2014-04-29 Galantos Pharma Gmbh Derivatives of galantamine as pro-drugs for the treatment of human brain diseases
CA2768668A1 (en) * 2009-07-23 2011-01-27 Shire Llc Galantamine amino acid and peptide prodrugs and uses thereof
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
EP3628315A1 (en) 2018-09-28 2020-04-01 Université de Caen Normandie Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases
CN113292420A (zh) * 2021-05-27 2021-08-24 神隆医药（常熟）有限公司 加兰他敏中间体原料2-溴-5-羟基-4-甲氧基苯甲酸回收方法
US12551491B1 (en) * 2025-07-23 2026-02-17 Alpha Cognition Inc. Dosage regimens for benzgalantamine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122665B1 (en) 1978-11-21 1982-08-31 Edinen Zentar Chim Process for preparing novel dienones of narvedine type and their derivatives
US4751306A (en) * 1985-09-09 1988-06-14 E. I. Du Pont De Nemours And Company Imide intermediates for the preparation of analgesic and/or antagonist octahydrobenzofuroisoquinolines
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
EP0363415B1 (en) * 1987-05-04 2008-10-15 Davis, Bonnie Compounds for the treatment of alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
CA1320486C (en) * 1988-06-01 1993-07-20 John J. Lafferty .alpha. -adrenergic receptor antagonists
EP0584185B1 (en) 1991-05-14 1999-08-11 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5231093A (en) * 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

Also Published As

Publication number Publication date
IL111274A (en) 2000-11-21
AU7581494A (en) 1995-05-04
CN1111245A (zh) 1995-11-08
EP0653427A1 (en) 1995-05-17
FI944821L (fi) 1995-04-16
JP2664344B2 (ja) 1997-10-15
EP1020470A2 (en) 2000-07-19
ATE212348T1 (de) 2002-02-15
FI108723B (fi) 2002-03-15
US5777108A (en) 1998-07-07
NO310415B1 (no) 2001-07-02
FI944821A0 (fi) 1994-10-13
TW363969B (en) 1999-07-11
PT653427E (pt) 2002-06-28
NO943893L (no) 1995-04-18
CZ287071B6 (en) 2000-08-16
AU696249B2 (en) 1998-09-03
JPH07188240A (ja) 1995-07-25
EG20472A (en) 1999-05-31
EP0653427B1 (en) 2002-01-23
IL111274A0 (en) 1994-12-29
RU2114850C1 (ru) 1998-07-10
PL177730B1 (pl) 2000-01-31
KR950011443A (ko) 1995-05-15
PL305456A1 (en) 1995-04-18
US6323195B1 (en) 2001-11-27
DE69429708T2 (de) 2002-08-29
KR0169114B1 (ko) 1999-01-15
CA2118174C (en) 2000-01-18
RO114133B1 (ro) 1999-01-29
EP1020470A3 (en) 2000-07-26
ZA948062B (en) 1995-06-06
CN1039911C (zh) 1998-09-23
NO943893D0 (no) 1994-10-14
RU94036448A (ru) 1996-09-10
NZ264683A (en) 1998-03-25
DE69429708D1 (de) 2002-03-14
CA2118174A1 (en) 1995-04-16
CZ254694A3 (en) 1995-09-13
DK0653427T3 (da) 2002-04-15

Similar Documents

Publication Publication Date Title
ES2171428T3 (es) Derivados de galantamina, un procedimiento para su preparacion y su uso como medicamentos.
MX9300498A (es) Derivados de n-sulfonil-2-oxo-indol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2158876T3 (es) Derivado de galantamina, un procedimiento para su preparacion y su utilizacion como medicamento.
ES2170759T3 (es) Derivados de galantamina, un procedimiento para su preparacion y su uso como medicamentos.
SV1999000118A (es) Nuevos derivados de pirazol substituidos ref. lea 33188-sv
ES2147739T3 (es) Fosfonooximetil-eteres de derivados de taxano.
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
ES2086313T3 (es) Nuevos derivados de xantina con efecto antagonista de adenosina.
ES2076150T3 (es) Derivados de 3-alcoxi-2-hidroxipropil-celulosa y su uso en composiciones para la edificacion.
AR031975A1 (es) Compuestos analogos de (1r,cis)-4-(6-amino-9h-purin-9-il) -2-ciclopenteno-1-metanol, proceso para su preparacion, su uso en el tratamiento de infecciones virales, y envase que los contiene
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
AR011116A1 (es) Compuesto derivado de n-hidroxi-beta-sulfonil propionamida y composicion farmaceutica que lo contiene
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
ES2148476T3 (es) Derivados de azabicicloalcano n-substituidos como neurolepticos asf.
UY27760A1 (es) Nuevos derivados de pirrolidinio.
MX9301129A (es) Nuevas ciclosporinas y composiciones farmaceuticas que las contienen.
AR025091A1 (es) Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas.
ES2156024T3 (es) Derivados siliciados de benzo-x-azoles filtros, composiciones cosmeticas fotoprotectoras que los contienen y utilizaciones.
AR033800A1 (es) Derivados de 3-fenoxi-1-fenilacetileno sustituido, metodo para la preparacion de dichos derivados, composicion herbicida e inhibidora del crecimiento de las plantas, metodo para controlar el desarrollo de plantas perjudiciales, metodo para inhibir el desarrollo de plantas perjudiciales, y uso de dic
ES2178055T3 (es) Derivados aminicos substituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR021596A1 (es) Compuestos que inhiben la procolageno c-proteinasa.
ES2160602T3 (es) Derivados de quinolona y acridinona para el tratamiento de la incontinencia urinaria.
ES2107035T3 (es) Derivados de 3-azabiciclo(3.2.0)heptano n-substituidos como neurolepticos etc..
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
AR004474A1 (es) Compuestos de 10-aminoalifatil-dibenz [b,f]oxepinas antineurodegenerativamente activas, utiles para el tratamiento de estados neurodegenerativos y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 653427

Country of ref document: ES